| AASLD

Home

PREDICTORS OF HOSPITAL-RELATED OUTCOMES OF COVID-19 INFECTION IN LIVER TRANSPLANT RECIPIENTS IN UNITED STATES: A NATIONWIDE INPATIENT STUDY

Read more about PREDICTORS OF HOSPITAL-RELATED OUTCOMES OF COVID-19 INFECTION IN LIVER TRANSPLANT RECIPIENTS IN UNITED STATES: A NATIONWIDE INPATIENT STUDY

<div>Background:

EARLY GRAFT FAILURE AFTER LIVING DONOR LIVER TRANSPLANT

Read more about EARLY GRAFT FAILURE AFTER LIVING DONOR LIVER TRANSPLANT

<div>Background: Living donor liver transplantation (LDLT) has been increasing in the United States (US). While data exists on longer-term patient and graft outcomes, a contemporary analysis of short-term outcomes is needed to better understand risk factors and opportunities for improvement.

IMPACT OF COMORBIDITIES ON LIVER TRANSPLANTATION: A PROSPECTIVE AND MULTICENTRIC ANALYSIS

Read more about IMPACT OF COMORBIDITIES ON LIVER TRANSPLANTATION: A PROSPECTIVE AND MULTICENTRIC ANALYSIS

<div>Background: Comorbidity plays an important role in the mortality of patients both on the waiting list and after liver transplantation (LT). To analyze the impact of comorbidities on LT, a prospective and multicentre study (HEPA_TIC) has been launched.

ESTIMATING GFR IN PATIENTS WITH DECOMPENSATED CIRRHOSIS AWAITING TRANSPLANT: UPDATED GRAIL WITHOUT RACE PERFORMS BETTER THAN CKD EPI 2021

Read more about ESTIMATING GFR IN PATIENTS WITH DECOMPENSATED CIRRHOSIS AWAITING TRANSPLANT: UPDATED GRAIL WITHOUT RACE PERFORMS BETTER THAN CKD EPI 2021

<div> 
Background:

A PHASE 2b, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND TREATMENT REGIMENS OF VTP-300 COMBINED WITH LOW-DOSE NIVOLUMAB IN CHRONIC HEPATITIS B INFECTION

Read more about A PHASE 2b, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND TREATMENT REGIMENS OF VTP-300 COMBINED WITH LOW-DOSE NIVOLUMAB IN CHRONIC HEPATITIS B INFECTION

<div>Background: New treatment concepts focus on enhancing rates of functional cure of chronic hepatitis B (HBV) with the aims of stopping nucleos(t)ide treatment (NA) with no risk of virological relapse or liver disease progression and further decreasing the risk of hepatocellular carcinoma (HCC). Induction of a CD8+ T cell response to HBV is likely a required mechanism to achieve a functional cure.

IMPACT OF SOCIAL DETERMINANTS OF HEALTH ON TIME TO TREATMENT INITIATION AND PROGRESSION OF HEPATOCELLULAR CANCER

Read more about IMPACT OF SOCIAL DETERMINANTS OF HEALTH ON TIME TO TREATMENT INITIATION AND PROGRESSION OF HEPATOCELLULAR CANCER

<div>Background: While studies have associated social determinants of health (SDOH) with hepatocellular carcinoma (HCC) treatment delay of >3 months, there is limited data on SDOH impacting expedited treatment and subsequent outcomes. This study investigates whether components of SDOH are associated with progression-free survival for HCC within Milan criteria and their effect on time to initiate HCC treatment.

NON-ALCOHOLIC STEATOHEPATITIS (NASH) HAS BECOME THE MOST COMMON INDICATION FOR LIVER TRANSPLANTATION AMONG CANDIDATES WITH HEPATOCELLULAR CARCINOMA IN THE UNITED STATES

Read more about NON-ALCOHOLIC STEATOHEPATITIS (NASH) HAS BECOME THE MOST COMMON INDICATION FOR LIVER TRANSPLANTATION AMONG CANDIDATES WITH HEPATOCELLULAR CARCINOMA IN THE UNITED STATES

<div>Background: High prevalence of obesity in the U.S. is driving the burden of non-alcoholic steatohepatitis (NASH) and associated adverse clinical outcomes including NASH-related end-stage liver disease and hepatocellular carcinoma (HCC). Our aim was to assess the most recent trends in patients with chronic liver disease (CLD) listed for liver transplantation (LT) in the U.S. using a national registry.

ARTIFICIAL INTELLIGENCE TO MEASURE FIBROSIS CHANGE ON LIVER BIOPSY IN MAESTRO-MASH: A PHASE 3 SERIAL LIVER BIOPSY STUDY IN 966 PATIENTS WITH MASH TREATED WITH RESMETIROM OR PLACEBO

Read more about ARTIFICIAL INTELLIGENCE TO MEASURE FIBROSIS CHANGE ON LIVER BIOPSY IN MAESTRO-MASH: A PHASE 3 SERIAL LIVER BIOPSY STUDY IN 966 PATIENTS WITH MASH TREATED WITH RESMETIROM OR PLACEBO

<div>Background: MAESTRO-MASH (NCT03900429), an ongoing, randomized, double-blind, placebo-controlled Phase 3 serial liver biopsy study, achieved both primary endpoints on liver biopsy (MASH resolution and fibrosis reduction) at Week 52 with both resmetirom doses, including a ≥1-stage reduction in fibrosis without worsening of MASH of 24%, 26% (mITT) at 80 and 100 mg resmetirom compared with placebo (14%).

PREDICTORS OF RENAL RECOVERY AND SURVIVAL OUTCOMES IN LIVER TRANSPLANT RECIPIENTS MEETING SLK ELIGIBILITY CRITERIA

Read more about PREDICTORS OF RENAL RECOVERY AND SURVIVAL OUTCOMES IN LIVER TRANSPLANT RECIPIENTS MEETING SLK ELIGIBILITY CRITERIA

<div>Background: The 2017 UNOS simultaneous liver-kidney transplant (SLK) policy establishes the minimum eligibility criteria for SLK listing and a mechanism to expedite kidney after liver transplantation (Safety Net). Candidate selection for SLK versus Safety Net requires further refinement.

INCREASING LIVER STIFFNESS VALUES ABOVE 20 KILOPASCALS ARE ASSOCIATED WITH HIGHER RISKS OF DECOMPENSATED CIRRHOSIS AND MORTALITY BUT NOT HCC

Read more about INCREASING LIVER STIFFNESS VALUES ABOVE 20 KILOPASCALS ARE ASSOCIATED WITH HIGHER RISKS OF DECOMPENSATED CIRRHOSIS AND MORTALITY BUT NOT HCC

<div>Background: FibroScan®-derived liver stiffness (LS) values above a threshold of 20 kilopascals (kPa) has been used to guide endoscopic screening for gastro-esophageal varices. However, there is limited data on the clinical significance of LS values above this threshold. We aimed to assess whether LS values ≥ 20 kPa are associated with death, decompensation, and hepatocellular carcinoma (HCC).

Subscribe to